Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy¹

SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction (ARR) into the Prolaris^® Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy. Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT)¹.

ADT can be effective at slowing the progression of prostate cancer, but it can also be associated with significant side effects such as bone and muscle loss, weight gain and increased cardiovascular risk. In addition to helping identify those patients who can safely forego ADT, the latest Prolaris enhancement will now provide patients with an individual assessment of how adding ADT to radiation therapy may reduce their risk of metastasis over 10 years.

“When men are diagnosed with localized prostate cancer, they have choices about different kinds of therapies. Often they’re considering combining therapies together or just doing an individual therapy,” said Dr. Jonathan Tward, MD, PhD, at the Huntsman Cancer Institute at the University of Utah. “With the Prolaris test physicians can now counsel patients on whether adding ADT to their treatment plan may reduce their individualized risk of metastasis. This offers increased clarity to make informed decisions, balancing the potential side effects of ADT.”

At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Tward presented a study that found Prolaris can predict the ARR of metastasis when ADT is added to RT regardless of National Comprehensive Cancer Network^® risk group. When a patient’s Prolaris results fell below the multi-modal treatment threshold, adding ADT to RT resulted in an average ARR of 0.86%, implying minimal benefits against potential side effects. However, for those above the threshold, adding ADT to RT yielded an average ARR of 8.2%, indicating a more meaningful benefit from ADT that could outweigh the possible side effects.

“Determining how much a patient benefits from ADT versus the side effects is critical to making the best treatment decisions for patients with prostate cancer,” said Terry White, General Manager of Urology, Myriad Genetics. “With the addition of Absolute Risk Reduction to the Prolaris report, patients and their providers can have a more personalized risk-benefit discussion and decide on the most effective treatment path.”

For more information about Prolaris, visit: https://myriad.com/urology/understanding-the-prolaris-report/

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.  

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the addition of Absolute Risk Reduction to Prolaris and that the addition of ARR will provide patients with an individual assessment of how adding ADT to radiation therapy may reduce their risk of metastasis over 10 years. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on March 1, 2023, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

1 Tward JD, et al. Predicting Absolute Benefit in Risk of Metastasis of Androgen Deprivation Therapy added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer. JCO 41, no. 16_suppl (June 01, 2023)5030